Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

354,475 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/03/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/03/2020.
Displaying: 1,102 trials in your specialties ()
View trials across your selected specialties

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Chronic Lymphocytic Leukemia
View Full Trial
INTERVENTION

Drug: GA101, Drug: ibrutinib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

UCSD Moores Cancer Center, La Jolla, California, United States

Brief Summary

The purpose of the study is to determine whether ibrutinib in combination with GA101 - Obinutuzumab might be useful for the treatment of CLL. This study will evaluate if ibrutinib in combination with GA101 - Obinutuzumab can reduce the amount of cancerous cells in body.

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Post-transplant Lymphoproliferative Disorder, B-Cell Prolymphocyt...
View Full Trial
INTERVENTION

Drug: cyclophosphamide, Other: laboratory biomarker analysis, Drug: Bendamustine Hydrochloride, Drug: Etoposide, Drug: Fludarabine Phosphate, Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

City of Hope Medical Center, Duarte, California, United States

Brief Summary

This phase I trial studies the side effects and best dose of cellular immunotherapy following chemotherapy in treating patients with non-Hodgkin lymphomas, chronic lymphocytic leukemia or B-cell prolymphocytic leukemia that has come back. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Relapsed Multiple Myeloma, Refractory Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Nivolumab, Drug: Ixazomib, Drug: Dexamethasone, Drug: Cyclophosphamide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Brief Summary

This research is being done to assess the effectiveness and safety of the combination of nivolumab with ixazomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Daratumumab Subcutaneous (SC) Administration, Drug: Recombinant Human Hyaluronidase [rHuPH20]) SC Administration

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Winship Cancer Institute Emory University, Atlanta, Georgia, United States

Brief Summary

The purpose of the study is to evaluate the pharmacokinetics and safety from the mixture of daratumumab and rHuPH20 prepared immediately before administration via Subcutaneous (SC) delivery (Part 1) and CF (co-formulated daratumumab and rHuPH20 preparation) administration via SC delivery of daratumumab (Part 2) and to evaluate the safety of Dara-CF 1800 milligram (mg) SC delivery without pre-dose and post-dose corticosteroids (Part 3).

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Drug: AMG 224

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Research Site, West Hollywood, California, United States

Brief Summary

This is a first in human phase 1 multicenter open label study in subjects with relapsed or refractory multiple myeloma.

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma...
View Full Trial
INTERVENTION

Procedure: Autologous Hematopoietic Stem Cell Transplantation, Drug: Busulfan, Drug: Gemcitabine Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Melphalan, Drug: Panobinostat, Procedure: Peripheral Blood Stem Cell Transplantation, Other: Pharmacological Study

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

M D Anderson Cancer Center, Houston, Texas, United States

Brief Summary

This phase II trial studies how well panobinostat, gemcitabine hydrochloride, busulfan, and melphalan before stem cell transplant work in treating patients with multiple myeloma that does not respond to treatment (refractory) or has returned (relapsed). Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving high-dose chemotherapy, such as gemcitabine hydrochloride, busulfan, and melphalan, before a peripheral blood stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. Previously collected stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.

Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Lower-risk Myelodysplastic
View Full Trial
INTERVENTION

Drug: ASTX727, Drug: ASTX727, Drug: ASTX727, Drug: ASTX727, Drug: ASTX727

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

NTT Medical Center Tokyo, Tokyo, Japan

Brief Summary

To investigate the tolerability and safety of ASTX727 in Japanese subjects with lower-risk MDS.

Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Multiple Myeloma Stage I
View Full Trial
INTERVENTION

Combination Product: Cyclo Thal Dex Daratumumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

CEHON - Centro de Hematologia e Oncologia da Bahia, Salvador, Bahia, Brazil

Brief Summary

The best induction protocol to eligible multiple myeloma patients was not established. Combination of three drugs demonstrated better outcomes than two drugs combo. Nevertheless, until now four drugs combo did not prove gain against three drugs One of the three drugs protocol studied as induction was CTD scheme (cyclophosphamide+ thalidomide+dexamethasone). Daratumumab has a novel mechanism of action that results in enhanced activity in combination with existing standards of care, including first-generation novel agents, such as thalidomide, as well as other therapeutics. Considerable responses have been observed in a cohort of heavily pretreated patients with relapsed/refractory MM. The use of a treatment combination with monoclonal antibody associated with immunomodulator (in a four drug combo) can lead to a improvement in response rates and in survival, reflects on a better free time interval. This trial will represent a new option of treatment with a combination of anti CD38 monoclonal antibody (DARATUMUMAB) as induction regimen with CTD protocol (four drug combination). And It use as consolidation and maintenance to give better immunomodulatory response and extended survival and disease control.

Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Combination Product: Ixazomib and Daratumumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

CHU CAEN Dept of Hematology, Caen, France

Brief Summary

Multiple myeloma is an incurable hematological malignancy that affects older patients. Currently, despite recent progress, the disease relapses more or less quickly after initial treatment and requires the resumption of treatment with new drugs associated with cortisone, whose side effects are important. The investigators propose to conduct a phase 2 testing the combination ixazomib - daratumumab without dexamethasone.

A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Myelodysplastic Syndromes
View Full Trial
INTERVENTION

Drug: LB-100

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Brief Summary

The purpose of this study is to test the safety and efficacy (benefits) of an investigational drug LB-100, for treatment of myelodysplastic syndromes. LB-100 has previously been administered to patients with various solid tumors. In this study, LB-100 will be administered as an intravenous infusion over 120 minutes. This study will be conducted in 2 phases. In phase Ib, escalating doses of LB-100 will be administered to patients to study the safety and to determine a safe dose of LB-100. In phase 2, patients will be administered LB-100 at the dose that was found to be safe in phase Ib. The efficacy (benefits) and safety of LB-100 will be determined in this phase of the study.